Systematic review assesses efficacy of biologics in chronic rhinosinusitis with nasal polyps, suggesting therapeutic benefits of dupilumab and stapokibart.
Summary Compared to placebo, Dupilumab and Stapokibart (CM310) demonstrate the most significant therapeutic efficacy in treating CRSwNP. All biologics demonstrated favourable safety profiles, with Dupilumab exhibiting the lowest risk of adverse events.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: